Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (HORIZON)

In by ECIR

Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (HORIZON)

  • Hidden
  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria
  1. Male or Female 18 to 80 years of age
  2. Lp(a) ≥ 70 mg/dL
  3. CVD with ≥ 1 of the following:
    • MI ≥ 3 months and ≤ 10 years
    • Stroke ≥ 3 months and ≤ 10 years
    • PAD: intermittent claudication with ABI ≤ 0.9 and/or lower limb amputation, or revascularization due to limb ischemia
  4. Treated with optimal lipid-lowering therapy
Exclusion Criteria
  1. MI, stroke, coronary or lower limb revascularization within 3 months
  2. History of Hemorrhagic stroke or major bleeding event
  3. Treatment with Niacin within 3 months
  4. Plts < 140,000/mm3
  5. GFR ≤ 30 ml/min
  6. UACR > 500 mg/g
  7. HF NYHA Class IV
Back to Current Studies